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Introduction: Cataract surgery is one of the most com-
monly performed surgeries, and patients over the age of 
60 are major candidates for this procedure. Hypertension 
is one of the most commonly reported diseases in this age 
group. Since hypertension is associated with poor surgery 
outcomes, it is important to find appropriate medications 
for controlling the optimal blood pressure of patients. 
Therefore, the present study aimed to compare the ef-
fect of labetalol and hydralazine on blood pressure during 
cataract surgery.
Materials and Methods: A total of 63 patients undergo-
ing cataract surgery in 2014-2015 were enrolled in this 
clinical trial, and randomly assigned to the hydralazine 
group (n=30) and the labetalol group (n=33). Systolic, 
diastolic, and mean arterial blood pressure and heart rate 
were recorded at 0, 5, 10, and 15 minutes.
Findings: Changes in the heart rate were similar in both 
groups and had an increasing trend from baseline to 15 
minutes. In terms of changes in blood pressure after drug 
injection, labetalol resulted in a more rapid decrease in sys-
tolic, diastolic, and mean arterial blood pressures than hy-
dralazine, so that their values were significantly lower in the 
labetalol group than the hydralazine group  after 5 minutes.
Conclusion: Both labetalol and hydralazine seem to be 
suitable for controlling blood pressure during surgery. 
However, the more rapid effect of labetalol than hydrala-
zine on lowering blood pressure and the reflex tachycar-
dia, observed most often with hydralazine, should be con-
sidered when selecting them.
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ataract surgery is one of the most com-
monly performed surgeries, and patients 
over the age of 60 are major candidates 
for this procedure1. Non-ophthalmic complications of 
cataract surgery occur in 2% to 15% of cases. The most 
common complications are hypertension, bronchocon-
striction, and arrhythmia which account for 90% of the 
cataract surgery-related non-ophthalmic adverse events2. 
Given the negligible physiologic effects of the eye, most 
of the eye surgeries, including cataract surgery, are con-
sidered low-risk surgical procedures3. However, two-thirds 
of patients undergoing cataract surgery have at least one 
chronic illness. Hypertension is one of the most commonly 
reported diseases occurring in about 50% of these cases. 
In fact, the high prevalence of hypertension in these pa-
tients can be justified by the increasing prevalence of hy-
pertension with age4.
Perioperative hypertension may arise from the following 
conditions:
• Induction of anesthesia
• Pain-induced sympathetic reflex resulting in general va-
soconstriction during surgery
• Surgical pain, hypothermia, hypoxia, and overhydration-
induced increase in intravascular volume after anesthesia
• Extracellular to intravascular fluid shift 24 to 48 hours 
after surgery 
• Discontinuation of antihypertensive agents as one of the 
most important causes
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Although the absolute cause of perioperative hyperten-
sion is unclear, the incidence of these events during cata-
ract surgery can be associated with anxiety, pain, and the 
use of intra-ophthalmic vasoconstrictors such as epineph-
rine5. The existing evidence suggests that hypertensive pa-
tients, even with proper preoperative control of hyperten-
sion, are prone to hypertension in the preoperative period. 
It is also likely that blood pressure of known cases that are 
under antihypertensive therapy has not been controlled 
adequately before the operation, because evidence sug-
gests that 50% of those who are aware of their hyperten-
sion are treated appropriately6.
The data indicate that preoperative diastolic pressure of 
above 110 is a predictive marker for cardiac complications 
in patients with a history of chronic hypertension. In ad-
dition, patients with a history of uncontrolled blood pres-
sure (>180/95) have a significant increase in postoperative 
neurologic deficits7. In multivariate analysis of preopera-
tive risk factors in non-cardiac surgeries in men, preopera-
tive hypertension increased the death rate to 2.8 times 
than those with normal blood pressure8. It has also been 
shown that high systolic blood pressure is associated with 
an increased incidence of silent myocardial ischemia in 
the perioperative period9. Given the mentioned complica-
tions, arterial blood pressure control during surgery is of 
great importance.
Acute hypertension episodes are treated with intrave-
nous esmolol, labetalol, nitroprusside, nitroglycerin, and 
hydralazine. Labetalol is a mixed alpha- and beta-adren-
ergic antagonist which is used for the treatment of hy-
pertension10. This drug is a combination of the selective 
competitive blocking effect of alpha-1 adrenergic activ-
ity and non-selective competitive blocking effect of beta-
adrenergic activity; the alpha-beta ratio in the intravenous 
injection is about 1 to 711. The main physiological function 
of this drug arises from the blockage of beta-1 receptors 
in the myocardium, beta-2 receptors in the bronchus and 
smooth muscles of the vascular walls, and alpha-1 recep-
tors of vascular muscle. This function ultimately results in 
lowering blood pressure and systemic vascular resistance 
without significantly reducing heart rate, cardiac output, 
or stroke volume12. Labetalol is administered through bo-
lus intravenous injection or continuous infusion. Its ef-
fect starts in 2 to 5 min, reaches its peak in 5 to 15 min, 
and lasts 2 to 4 hours, and has a half-life of 5.5 hours. 
Labetalol can be prescribed at a dose of 20 mg and then 
increased to 20-80 mg every 10 minutes to achieve the 
desired blood pressure. It can also be infused at a dose of 
1 to 2 mg per minute after the initial 20 mg13.
Due to beta-blocking effects, the heart rate remains steady 
or decreases slightly. Unlike pure beta-blockers, the car-
diac output does not change15. Hydralazine is an arterial 
vasodilator with a direct effect and is used as the first line 
medicine for the treatment of hypertension crisis in preg-
nancy and can cause a rapid decrease in arterial blood 
pressure. Hydralazine seems to affect diastolic blood pres-
sure more than systolic blood pressure14. Its effect begins 
in about 5 to 15 minutes when administered intravenous-
ly, and lasts last up to 12 hours. However, its maximum 
effect is between 10 and 80 minutes when administered 
orally14. Although the circulating half-life of hydralazine is 
only about 3 hours, its effective half-life is estimated to be 
10 hours15. Reduced resistance of peripheral vessels leads 
to a reflex tachycardia and can increase cardiac output16. 
Although these two drugs are extensively used, there is 
currently not enough evidence on their effectiveness and 
side effects during cataract surgery in people with hyper-
tension. Therefore, the present study aimed to compare 
these medicines.
Procedure
After approving the university’s ethics committee and ob-
taining written consent for participating in the study, a 
total of 63 patients who visited the Farabi Hospital for 
cataract surgery were enrolled in this randomized, dou-
ble-blind clinical trial. Inclusion criteria were candidacy 
for cataract surgery and a history of mild and moderate 
hypertension treatment. Exclusion criteria were a contra-
indication of the study drugs, not controlling hyperten-
sion before surgery, a history of severe asthma or severe 
COPD with a history of hospitalization, cardiac blocks I 
and II, severe bradycardia (heart rate <50/min), and hav-
ing a pacemaker. Standard monitoring and sedation were 
identical in both groups. After entering the operating 
room and checking the vital signs under standard moni-
toring, sedative drugs including 1 mg midazolam and 1 
μg/kg fentanyl were administered intravenously. Five min-
utes after administration of fentanyl and midazolam, the 
patient’s vital signs including systolic and diastolic blood 
pressure, arterial blood pressure, heart rate, and arterial 
hemoglobin saturation were recorded. Written consent 
for participation in the study was obtained from patients 
with blood pressures of higher than 160/100. The inter-
vention groups were:
Hydralazine group: In this group, 10 mg (half an am-
poule) of bolus hydralazine was injected intravenously and 
the surgery was started 15 minutes later; if blood pressure 
was not controlled (or not declined more than 20%), 10 
mg hydralazine was re-injected intravenously.
Labetalol Group: The patients in this group received 2 
mL (equivalent to 20 mg) of bolus labetalol intravenously. 
The surgery was started 15 min later and the vital signs 
were recorded every 5 min (at 5, 10, and 15 min). If the 
patients’ blood pressure was not controlled (or not de-
clined more than 20%) after 10 min, an additional dose 
of 2 mL of labetalol was re-injected. If blood pressure was 
not controlled after re-injection, the patient was known 
to be resistant to labetalol and hence a bolus of 50-100 
μg TNG was used to control blood pressure. In addition, 
if blood pressure was decreased by more than 40% or 
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portive measures, including serum therapy and injection 
of atropine and vasoconstrictor, were taken to increase 
blood pressure. The vital signs were also recorded during 
the recovery, after the end of the operation, and all data, 
demographic variables, and the need for re-injection were 
analyzed.
Measured variables
The variables measured in this study included systolic and 
diastolic blood pressure and mean heart rate. Other risk 
factors that were studied included the history of hyper-
tension, diabetes, ischemic heart disease, kidney failure, 
heart failure, liver failure, thyroid disease, and asthma or 
mild COPD.
Data analysis
The data were analyzed in SPSS 20 through frequency 
percentage, central statistical indices such as mean, and 
dispersion indices such as standard deviation, and the 
desired charts were plotted. Chi-Square test was used to 
determine the relationship between qualitative variables. 
Differences between quantitative variables were assessed 
by independent sample t-test. Changes in the variables 
before and after each action were evaluated by paired 
samples t-test.
Ethical considerations
The information was recorded confidentially according to 
the principles of the Helsinki Declaration, and the patients 
were given the necessary explanations.
he collected data were analyzed in SPSS 20. 
A total of 63 eligible patients were enrolled in 
this study. According to the randomized four-
block table, 30 patients were entered in the hydralazine 
group and 33 in the labetalol group. In this study, the 
mean age was 67.80±7.31 years, ranging from 52 to 86 
years. The mean age of patients was 67.54±7.54 years in 
the hydralazine group and 68.09±7.20 years in the labet-
alol group, and there was no statistically significant differ-
ence between them (p=0.752). In addition, 36 patients 
(57.1%) were male and 27 (42.9%) were female. The 
hydralazine group consisted of 15 male and 15 female 
patients and the labetalol group consisted of 21 male 
and 12 female patients with no significant difference 
(p=0.316). Comorbidity existed in 32 patients (50.8%) 
and 31 patients (49.2%) had no history of other diseases. 
Figure 4-4 shows the differences between the two groups 
for the presence of comorbidity. According to the analysis, 
there was no statistically significant difference between 
the two groups (p=0.904).
Table 1: Differences between hydralazine and labetalol 
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Systolic BP at 0 min
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Diastolic BP at 0 min
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MAP at 0 min
MAP at 5 min
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MAP
egarding the insignificant difference be-
tween the two groups in terms of demo-
graphic variables, an appropriate match-
ing seems to exist between the groups in the present 
study and there are no confounding factors in terms of 
demographic variables. Changes in the heart rate of the 
patients of both groups were similar and the heart rate 
gradually increased from baseline to 15 minutes afterward. 
Differences between the two groups were not statistically 
significant and the changes observed in the heart rate of 
the patients may be justified according to the decrease in 
blood pressure after the injection of drugs and the release 
of catecholamines during surgery17,18. Regarding the reflex 
tachycardia following administration of hydralazine, other 
studies have also achieved similar results, but unlike the 
current study, some studies have reported a decrease in 
the heart rate due to the use of labetalol16,19,20.
In addition, the mean systolic and diastolic blood pressure 
at baseline was slightly higher in the labetalol group than 
the hydralazine group, but after the injection of drugs, 
both systolic and diastolic blood pressures were decreased 
more rapidly in the labetalol group than the hydralazine 
group, so that their values were significantly lower in the 
labetalol group than the hydralazine  group from the 5th 
minute afterward. Gradually, hydralazine also exerted its 
effect over time and reduced the observed difference in 
the mean blood pressure between the two groups. Dimich 
et al. had similar results and presented both compounds 
as appropriate drugs for controlling the pressure during 
surgery16. Vigil De Gracia et al. also found similar results 
on gestational hypertension21. Changes in arterial blood 














oth labetalol and hydralazine seem to be 
suitable for controlling blood pressure dur-
ing surgery. However, the more rapid effect 
of labetalol than hydralazine on lowering blood pressure 
and the reflex tachycardia, observed most often with hy-
dralazine, as well as the surgery type should be considered 
when selecting them.
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